{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:55:26Z","timestamp":1787183726773,"version":"build-2736575974"},"reference-count":299,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,1,22]],"date-time":"2022-01-22T00:00:00Z","timestamp":1642809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA252720"],"award-info":[{"award-number":["R01 CA252720"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Uncontrolled inflammation is a salient factor in multiple chronic inflammatory diseases and cancers. In this review, we provided an in-depth analysis of the relationships and distinctions between uncontrolled inflammation, fibrosis and cancers, while emphasizing the challenges and opportunities of developing novel therapies for the treatment and\/or management of these diseases. We described how drug delivery systems, combination therapy and the integration of tissue-targeted and\/or pathways selective strategies could overcome the challenges of current agents for managing and\/or treating chronic inflammatory diseases and cancers. We also recognized the value of the re-evaluation of the disease-specific roles of multiple pathways implicated in the pathophysiology of chronic inflammatory diseases and cancers\u2014as well as the application of data from single-cell RNA sequencing in the success of future drug discovery endeavors.<\/jats:p>","DOI":"10.3390\/cancers14030552","type":"journal-article","created":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T20:32:52Z","timestamp":1642969972000},"page":"552","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Inflammation, Fibrosis and Cancer: Mechanisms, Therapeutic Options and Challenges"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7381-9506","authenticated-orcid":false,"given":"Bocheng","family":"Wu","sequence":"first","affiliation":[{"name":"School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA 30332, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quaovi H.","family":"Sodji","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2248-9551","authenticated-orcid":false,"given":"Adegboyega K.","family":"Oyelere","sequence":"additional","affiliation":[{"name":"School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA 30332, USA"},{"name":"Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA 30332, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Inflammation and cancer: Triggers, mechanisms, and consequences","volume":"51","author":"Greten","year":"2019","journal-title":"Immunity"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4103\/aam.aam_56_18","article-title":"Inflammation and cancer","volume":"18","author":"Singh","year":"2019","journal-title":"Ann. Afr. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1183\/09031936.00115112","article-title":"A progression-free end-point for idiopathic pulmonary fibrosis trials: Lessons from cancer","volume":"41","author":"Vancheri","year":"2013","journal-title":"Eur. Respir. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.immuni.2011.09.006","article-title":"Tumor promotion via injury-and death-induced inflammation","volume":"35","author":"Kuraishy","year":"2011","journal-title":"Immunity"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Elliot, A., Myllym\u00e4ki, H., and Feng, Y. (2020). Inflammatory Responses during Tumour Initiation: From Zebrafish Transgenic Models of Cancer to Evidence from Mouse and Man. Cells, 9.","DOI":"10.20944\/preprints202003.0254.v1"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1038\/onc.2013.272","article-title":"Inflammatory chemokines and metastasis\u2014Tracing the accessory","volume":"33","author":"Borsig","year":"2014","journal-title":"Oncogene"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Kinoshita, T., and Goto, T. (2019). Molecular mechanisms of pulmonary fibrogenesis and its progression to lung cancer: A review. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061461"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Ballester, B., Milara, J., and Cortijo, J. (2019). Idiopathic pulmonary fibrosis and lung cancer: Mechanisms and molecular targets. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20030593"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Noguchi, S., Saito, A., and Nagase, T. (2018). YAP\/TAZ signaling as a molecular link between fibrosis and cancer. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19113674"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1183\/09031936.00077309","article-title":"Idiopathic pulmonary fibrosis: A disease with similarities and links to cancer biology","volume":"35","author":"Vancheri","year":"2010","journal-title":"Eur. Respir. J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.trsl.2019.02.006","article-title":"The double edge sword of fibrosis in cancer","volume":"209","author":"Chandler","year":"2019","journal-title":"Transl. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/cpt.789","article-title":"Cancer-related systemic inflammation: The challenges and therapeutic opportunities for personalized medicine","volume":"102","author":"Shinko","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.matbio.2017.11.010","article-title":"Inflammation and fibrosis","volume":"68","author":"Mack","year":"2018","journal-title":"Matrix Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"529075","DOI":"10.3389\/fphys.2020.529075","article-title":"The dynamic interplay between cardiac inflammation and fibrosis","volume":"11","author":"Thomas","year":"2020","journal-title":"Front. Physiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1084\/jem.20181739","article-title":"Modulating inflammation for cancer therapy","volume":"216","author":"Ritter","year":"2019","journal-title":"J. Exp. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fphar.2014.00051","article-title":"Mechanisms of cellular fibrosis associated with cancer regimen-related toxicities","volume":"5","author":"Mancini","year":"2014","journal-title":"Front. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-06924-5","article-title":"SUMOylation of ROR-\u03b3t inhibits IL-17 expression and inflammation via HDAC2","volume":"9","author":"Singh","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s13765-017-0285-9","article-title":"Crosstalk between reactive oxygen species and pro-inflammatory markers in developing various chronic diseases: A review","volume":"60","author":"Ranneh","year":"2017","journal-title":"Appl. Biol. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1089\/ars.2012.5149","article-title":"Reactive oxygen species in inflammation and tissue injury","volume":"20","author":"Mittal","year":"2014","journal-title":"Antioxid. Redox Signal."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/AIA.0b013e318034194e","article-title":"Cytokines, inflammation and pain","volume":"45","author":"Zhang","year":"2007","journal-title":"Int. Anesthesiol. Clin."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7204","DOI":"10.18632\/oncotarget.23208","article-title":"Inflammatory responses and inflammation-associated diseases in organs","volume":"9","author":"Chen","year":"2018","journal-title":"Oncotarget"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.biocel.2003.12.003","article-title":"Tissue repair and the dynamics of the extracellular matrix","volume":"36","author":"Midwood","year":"2004","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1172\/JCI93557","article-title":"Extracellular matrix as a driver of progressive fibrosis","volume":"128","author":"Herrera","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"949157","DOI":"10.1155\/2012\/949157","article-title":"Innate immune cells in liver inflammation","volume":"2012","author":"Liaskou","year":"2012","journal-title":"Mediat. Inflamm."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2567.2009.03167.x","article-title":"Natural killer cells in infection and inflammation of the lung","volume":"128","author":"Culley","year":"2009","journal-title":"Immunology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3389\/fnins.2020.00142","article-title":"Cytotoxic immunity in peripheral nerve injury and pain","volume":"14","author":"Davies","year":"2020","journal-title":"Front. Neurosci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1016\/j.bbamcr.2014.04.017","article-title":"A dual role for the anti-apoptotic Bcl-2 protein in cancer: Mitochondria versus endoplasmic reticulum","volume":"1843","author":"Akl","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1038\/onc.2010.46","article-title":"Cross talk between stimulated NF-kappaB and the tumor suppressor p53","volume":"29","author":"Schneider","year":"2010","journal-title":"Oncogene"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7150\/ijms.3.47","article-title":"The natural history of hepatitis C virus (HCV) infection","volume":"3","author":"Chen","year":"2006","journal-title":"Int. J. Med. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Sauleda, J., Nunez, B., Sala, E., and Soriano, J.B. (2018). Idiopathic Pulmonary Fibrosis: Epidemiology, Natural History, Phenotypes. Med. Sci., 6.","DOI":"10.3390\/medsci6040110"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1136\/thx.2010.148031","article-title":"The rising incidence of idiopathic pulmonary fibrosis in the U.K","volume":"66","author":"Navaratnam","year":"2011","journal-title":"Thorax"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.chest.2020.08.016","article-title":"Mortality trends of idiopathic pulmonary fibrosis in the United States from 2004 through 2017","volume":"159","author":"Jeganathan","year":"2021","journal-title":"Chest"},{"key":"ref_34","unstructured":"The National Institute of Health (2021, July 20). Idiopathic Pulmonary Fibrosis, Available online: https:\/\/www.nhlbi.nih.gov\/health-topics\/idiopathic-pulmonary-fibrosis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1378\/chest.09-1002","article-title":"Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: A population-based study","volume":"137","author":"Daniels","year":"2010","journal-title":"Chest"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"00170","DOI":"10.1183\/23120541.00170-2018","article-title":"Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry","volume":"5","author":"Kaunisto","year":"2019","journal-title":"ERJ Open Res."},{"key":"ref_37","unstructured":"American Cancer Society (2021, November 09). Cancer Statistics Center. Available online: http:\/\/cancerstatisticscenter.cancer.org."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"822","DOI":"10.2106\/00004623-200205000-00022","article-title":"Muscle injuries and repair: Current trends in research","volume":"84","author":"Huard","year":"2002","journal-title":"J. Bone Jt. Surg. Am."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1113\/jphysiol.2007.127639","article-title":"Expression of collagen and related growth factors in rat tendon and skeletal muscle in response to specific contraction types","volume":"582","author":"Heinemeier","year":"2007","journal-title":"J. Physiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1146\/annurev-pathol-012513-104706","article-title":"Pathogenesis of idiopathic pulmonary fibrosis","volume":"9","author":"Wolters","year":"2014","journal-title":"Annu. Rev. Pathol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/path.4253","article-title":"Understanding the origin, activation and regulation of matrix-producing myofibroblasts for treatment of fibrotic disease","volume":"231","author":"Kramann","year":"2013","journal-title":"J. Pathol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/cr.2009.5","article-title":"TGF-beta-induced epithelial to mesenchymal transition","volume":"19","author":"Xu","year":"2009","journal-title":"Cell Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1111\/j.1442-2042.2007.01866.x","article-title":"Role of Wnt\/\u03b2-catenin signaling pathway in epithelial-mesenchymal transition of human prostate cancer induced by hypoxia-inducible factor-1\u03b1","volume":"14","author":"Jiang","year":"2007","journal-title":"Int. J. Urol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.1242\/jcs.00091","article-title":"Transforming growth factor-\u03b2 and epidermal growth factor synergistically stimulate epithelial to mesenchymal transition (EMT) through a MEK-dependent mechanism in primary cultured pig thyrocytes","volume":"115","author":"Grande","year":"2002","journal-title":"J. Cell Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/art.27382","article-title":"Selective expression of connective tissue growth factor in fibroblasts in vivo promotes systemic tissue fibrosis","volume":"62","author":"Sonnylal","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1046\/j.1523-1755.2002.00333.x","article-title":"Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation","volume":"61","author":"Strutz","year":"2002","journal-title":"Kidney Int."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"607483","DOI":"10.3389\/fcell.2020.607483","article-title":"The epithelial-to-mesenchymal transition as a possible therapeutic target in fibrotic disorders","volume":"8","author":"Robuffo","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.ajpath.2011.06.001","article-title":"Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders","volume":"179","author":"Li","year":"2011","journal-title":"Am. J. Pathol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.immuni.2016.02.024","article-title":"Tissue-resident macrophage ontogeny and homeostasis","volume":"44","author":"Ginhoux","year":"2016","journal-title":"Immunity"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1084\/jem.128.3.415","article-title":"The origin and kinetics of mononuclear phagocytes","volume":"128","author":"Cohn","year":"1968","journal-title":"J. Exp. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"13","DOI":"10.12703\/P6-13","article-title":"The M1 and M2 paradigm of macrophage activation: Time for reassessment","volume":"6","author":"Martinez","year":"2014","journal-title":"F1000prime Rep."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/imr.12220","article-title":"Mononuclear phagocytes of the intestine, the skin, and the lung","volume":"262","author":"Scott","year":"2014","journal-title":"Immunol. Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12931-018-0864-2","article-title":"Macrophages: Friend or foe in idiopathic pulmonary fibrosis?","volume":"19","author":"Zhang","year":"2018","journal-title":"Respir. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S2468-1253(19)30349-8","article-title":"The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990\u20132017: A systematic analysis for the Global Burden of Disease Study 2017","volume":"5","author":"Sepanlou","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/MEG.0000000000000341","article-title":"Rates of cirrhosis and hepatocellular carcinoma in chronic hepatitis B and the role of surveillance: A 10-year follow-up of 673 patients","volume":"27","author":"Poh","year":"2015","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in immunotherapy for hepatocellular carcinoma","volume":"18","author":"Sangro","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","article-title":"Cystic fibrosis","volume":"373","author":"Brian","year":"2009","journal-title":"Lancet"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1136\/thx.46.12.881","article-title":"Cystic fibrosis: Current survival and population estimates to the year 2000","volume":"46","author":"Elborn","year":"1991","journal-title":"Thorax"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.21037\/jtd.2017.07.85","article-title":"Outcomes after lung transplantation","volume":"9","author":"Thabut","year":"2017","journal-title":"J. Thorac. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMra1300109","article-title":"Origins of cystic fibrosis lung disease","volume":"372","author":"Stoltz","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_61","unstructured":"(2021, November 09). Reprinted from \u201cCystic Fibrosis Airway\u201d, by BioRender.com. Available online: https:\/\/app.biorender.com\/biorender-templates."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s40265-019-01233-7","article-title":"Elexacaftor\/ivacaftor\/tezacaftor: First approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e139983","DOI":"10.1172\/jci.insight.139983","article-title":"Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination","volume":"5","author":"Veit","year":"2020","journal-title":"JCI Insight"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s40272-017-0236-2","article-title":"Immunosuppression drug therapy in lung transplantation for cystic fibrosis","volume":"19","author":"Burcham","year":"2017","journal-title":"Pediatric Drugs"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/jnci\/95.5.381","article-title":"Cancer risk in nontransplanted and transplanted cystic fibrosis patients: A 10-year study","volume":"95","author":"Maisonneuve","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_66","first-page":"136","article-title":"Liver disease in cystic fibrosis","volume":"9","author":"Klincewicz","year":"2014","journal-title":"Prz. Gastroenterol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jcf.2012.11.010","article-title":"Cirrhosis and other liver disease in cystic fibrosis","volume":"12","author":"Flass","year":"2013","journal-title":"J. Cyst. Fibros."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2174\/1874306401206010063","article-title":"Drug induced interstitial lung disease","volume":"6","author":"Schwaiblmair","year":"2012","journal-title":"Open Respir. Med. J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"9","DOI":"10.37549\/AR2270","article-title":"Deciphering drug-induced interstitial lung disease: A mechanistic approach","volume":"45","author":"Ripley","year":"2016","journal-title":"Appl. Radiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev.me.39.020188.002143","article-title":"Mechanisms of drug-induced pulmonary disease","volume":"39","author":"Cooper","year":"1988","journal-title":"Annu. Rev. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/cncr.21324","article-title":"The role of radiotherapy in cancer treatment: Estimating optimal utilization from a review of evidence-based clinical guidelines","volume":"104","author":"Delaney","year":"2005","journal-title":"Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/nrc2587","article-title":"Normal tissue reactions to radiotherapy: Towards tailoring treatment dose by genotype","volume":"9","author":"Barnett","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/095530098142239","article-title":"Molecular and cellular basis of radiation fibrosis","volume":"73","author":"Burger","year":"1998","journal-title":"Int. J. Radiat. Biol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/0360-3016(94)00418-K","article-title":"Hepatic toxicity resulting from cancer treatment","volume":"31","author":"Lawrence","year":"1995","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(06)70580-0","article-title":"Oral complications of radiotherapy","volume":"7","author":"Sciubba","year":"2006","journal-title":"Lancet Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa0906260","article-title":"Long-term results of hypofractionated radiation therapy for breast cancer","volume":"362","author":"Whelan","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ijrobp.2005.03.047","article-title":"Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: Pulmonary function, prediction, and prevention","volume":"63","author":"Mehta","year":"2005","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.radonc.2020.11.020","article-title":"Idiopathic pulmonary fibrosis: Current knowledge, future perspectives and its importance in radiation oncology","volume":"155","author":"Turkkan","year":"2021","journal-title":"Radiother. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/S1470-2045(15)00417-9","article-title":"Radiotherapy in patients with connective tissue diseases","volume":"17","author":"Sciascia","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-019-0064-5","article-title":"Radiotherapy toxicity","volume":"5","author":"Niedermann","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3389\/fonc.2019.00467","article-title":"FLT-PET-CT for the Detection of Disease Recurrence After Stereotactic Ablative Radiotherapy or Hyperfractionation for Thoracic Malignancy: A Prospective Pilot Study","volume":"9","author":"Hiniker","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"692142","DOI":"10.3389\/fonc.2021.692142","article-title":"Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis","volume":"11","author":"Kartikasari","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1158\/2326-6066.CIR-13-0214","article-title":"IL-10: Master switch from tumor-promoting inflammation to antitumor immunity","volume":"2","author":"Oft","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/MIB.0000000000000236","article-title":"Cytokines, IBD, and colitis-associated cancer","volume":"21","author":"Francescone","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1183\/09031936.01.99055301","article-title":"Lung cancer in patients with idiopathic pulmonary fibrosis","volume":"17","author":"Park","year":"2001","journal-title":"Eur. Respir. J."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pupt.2017.03.016","article-title":"Lung cancer in patients with idiopathic pulmonary fibrosis","volume":"45","author":"Karampitsakos","year":"2017","journal-title":"Pulm. Pharm."},{"key":"ref_87","first-page":"98","article-title":"Chronic inflammation in cancer development","volume":"2","author":"Multhoff","year":"2011","journal-title":"Front. Immunol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1182\/blood-2017-06-780882","article-title":"Inflammation: A key regulator of hematopoietic stem cell fate in health and disease","volume":"130","author":"Pietras","year":"2017","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3389\/fonc.2018.00357","article-title":"Transforming growth factor-\u03b2-induced cell plasticity in liver fibrosis and hepatocarcinogenesis","volume":"8","author":"Fabregat","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.2174\/1389203718666171117112619","article-title":"TGF-beta and hepatocellular carcinoma: When a friend becomes an enemy","volume":"19","author":"Arrese","year":"2018","journal-title":"Curr. Protein Pept. Sci."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.cmi.2016.07.019","article-title":"Molecular mechanisms of hepatitis C virus-induced hepatocellular carcinoma","volume":"22","author":"Vescovo","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4103\/1319-3767.54743","article-title":"Helicobacter pylori infection in developing countries: The burden for how long?","volume":"15","author":"Salih","year":"2009","journal-title":"Saudi J. Gastroenterol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1128\/CMR.00011-10","article-title":"Helicobacter pylori and gastric cancer: Factors that modulate disease risk","volume":"23","author":"Wroblewski","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"714","DOI":"10.2174\/1566524015666150921105339","article-title":"Integrins as Therapeutic Targets for Respiratory Diseases","volume":"15","author":"Teoh","year":"2015","journal-title":"Curr. Mol. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1513\/pats.200708-146DR","article-title":"Biology of fibroblasts and myofibroblasts","volume":"5","author":"Phan","year":"2008","journal-title":"Proc. Am. Thorac. Soc."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Salton, F., Volpe, M.C., and Confalonieri, M. (2019). Epithelial(-)Mesenchymal Transition in the Pathogenesis of Idiopathic Pulmonary Fibrosis. Medicina, 55.","DOI":"10.3390\/medicina55040083"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1089\/jir.2018.0060","article-title":"Autoimmunity and cancer, the paradox comorbidities challenging therapy in the context of preexisting autoimmunity","volume":"39","author":"Valencia","year":"2019","journal-title":"J. Interf. Cytokine Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.3389\/fimmu.2017.01898","article-title":"Type 1 diabetes: A chronic anti-self-inflammatory response","volume":"8","author":"Clark","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/MPA.0b013e318209e05d","article-title":"Diabetes and pancreatic cancer: Chicken or egg?","volume":"40","author":"Magruder","year":"2011","journal-title":"Pancreas"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.3748\/wjg.14.3937","article-title":"Risk for colorectal cancer in ulcerative colitis: Changes, causes and management strategies","volume":"14","author":"Lakatos","year":"2008","journal-title":"World J. Gastroenterol. WJG"},{"key":"ref_101","first-page":"421","article-title":"Cyclosporin-A associated malignancy","volume":"1","author":"Durnian","year":"2007","journal-title":"Clin. Ophthalmol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"137823","DOI":"10.1155\/2015\/137823","article-title":"Transforming growth factor Beta family: Insight into the role of growth factors in regulation of fracture healing biology and potential clinical applications","volume":"2015","author":"Poniatowski","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"a005017","DOI":"10.1101\/cshperspect.a005017","article-title":"Cross talk among TGF-\u03b2 signaling pathways, integrins, and the extracellular matrix","volume":"3","author":"Munger","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1083\/jcb.200312172","article-title":"Integrin \u03b1V\u03b26-mediated activation of latent TGF-\u03b2 requires the latent TGF-\u03b2 binding protein-1","volume":"165","author":"Annes","year":"2004","journal-title":"J. Cell Biol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1083\/jcb.106.5.1659","article-title":"Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium","volume":"106","author":"Lyons","year":"1988","journal-title":"J. Cell Biol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1101\/gad.14.2.163","article-title":"Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis","volume":"14","author":"Yu","year":"2000","journal-title":"Genes Dev."},{"key":"ref_107","first-page":"1077","article-title":"Redox-mediated activation of latent transforming growth factor-beta 1","volume":"10","author":"Dix","year":"1996","journal-title":"Mol. Endocrinol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/1523-1747.ep12461198","article-title":"Thrombospondin in early human wound tissue","volume":"89","author":"Raugi","year":"1987","journal-title":"J. Investig. Dermatol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ejcb.2008.01.012","article-title":"Integrins and the activation of latent transforming growth factor beta1\u2014An intimate relationship","volume":"87","author":"Wipff","year":"2008","journal-title":"Eur. J. Cell Biol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1046\/j.1523-1747.2002.01641.x","article-title":"Transforming growth factor-beta signaling through the Smad pathway: Role in extracellular matrix gene expression and regulation","volume":"118","author":"Verrecchia","year":"2002","journal-title":"J. Investig. Dermatol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/cr.2008.328","article-title":"Non-Smad pathways in TGF-beta signaling","volume":"19","author":"Zhang","year":"2009","journal-title":"Cell Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2131","article-title":"Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype?","volume":"7","author":"Peinado","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.tibs.2013.10.001","article-title":"Signaling interplay between transforming growth factor-beta receptor and PI3K\/AKT pathways in cancer","volume":"38","author":"Zhang","year":"2013","journal-title":"Trends Biochem. Sci."},{"key":"ref_114","first-page":"299","article-title":"Targets of transcriptional regulation by two distinct type I receptors for transforming growth factor-\u03b2 in human umbilical vein endothelial cells","volume":"193","author":"Ota","year":"2002","journal-title":"J. Cell."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Guerrero, P.A., and McCarty, J.H. (2017). TGF-\u03b2 Activation and Signaling in Angiogenesis. Physiologic and Pathologic Angiogenesis-Signaling Mechanisms and Targeted Therapy, IntechOpen. Available online: https:\/\/www.intechopen.com\/chapters\/53316.","DOI":"10.5772\/66405"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/44334","article-title":"Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts","volume":"401","author":"Lyden","year":"1999","journal-title":"Nature"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nrd3810","article-title":"Targeting the TGF\u03b2 signalling pathway in disease","volume":"11","author":"Akhurst","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.trecan.2016.11.008","article-title":"Targeting TGF-\u03b2 signaling in cancer","volume":"3","author":"Colak","year":"2017","journal-title":"Trends Cancer"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"18632","DOI":"10.1073\/pnas.1318415110","article-title":"Combining two strategies to improve perfusion and drug delivery in solid tumors","volume":"110","author":"Stylianopoulos","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_120","first-page":"550","article-title":"Transforming growth factor-beta1 induces desmoplasia in an experimental model of human pancreatic carcinoma","volume":"61","author":"Lohr","year":"2001","journal-title":"Cancer Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/bcr287","article-title":"The complexities of breast cancer desmoplasia","volume":"3","author":"Walker","year":"2001","journal-title":"Breast Cancer Res"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12891-019-2486-3","article-title":"Investigating the effects of Pirfenidone on TGF-\u03b21 stimulated non-SMAD signaling pathways in Dupuytren\u2019s disease-derived fibroblasts","volume":"20","author":"Zhou","year":"2019","journal-title":"BMC Musculoskelet. Disord."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Hostettler, K., Zhong, J., Tamm, M., Lardinois, D., and Roth, M. (2014). Effect of pirfenidone on TGF-\u03b2-induced pro-fibrotic effects in primary human lung cells derived from patients with idiopathic pulmonary fibrosis. Eur. Respir. J., 44.","DOI":"10.1186\/s12931-014-0157-3"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.resinv.2017.09.007","article-title":"Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone","volume":"56","author":"Miura","year":"2018","journal-title":"Respir. Investig."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1039\/c0mb00115e","article-title":"Peptide ligands that use a novel binding site to target both TGF-\u03b2 receptors","volume":"6","author":"Li","year":"2010","journal-title":"Mol. BioSystems"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1365-2567.2011.03425.x","article-title":"Induction of latency-associated peptide (transforming growth factor-\u03b21) expression on CD4+ T cells reduces Toll-like receptor 4 ligand-induced tumour necrosis factor-\u03b1 production in a transforming growth factor-\u03b2-dependent manner","volume":"133","author":"Boswell","year":"2011","journal-title":"Immunology"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1007\/s13277-014-3002-x","article-title":"MAPK inhibitors differently modulate TGF-\u03b2\/Smad signaling in HepG2 cells","volume":"36","author":"Boye","year":"2015","journal-title":"Tumor Biol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1158\/2326-6066.CIR-14-0112","article-title":"NF-kappaB, an active player in human cancers","volume":"2","author":"Xia","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"7342","DOI":"10.1038\/sj.onc.1204926","article-title":"Transcriptional regulation of bcl-2 by nuclear factor \u03baB and its significance in prostate cancer","volume":"20","author":"Catz","year":"2001","journal-title":"Oncogene"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.1128\/MCB.21.16.5299-5305.2001","article-title":"NF-kappaB signals induce the expression of c-FLIP","volume":"21","author":"Micheau","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"ref_131","first-page":"725","article-title":"Constitutive NF-kappaB activity regulates the expression of VEGF and IL-8 and tumor angiogenesis of human glioblastoma","volume":"23","author":"Xie","year":"2010","journal-title":"Oncol. Rep."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1172\/JCI200421358","article-title":"NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression","volume":"114","author":"Huber","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1158\/1535-7163.MCT-13-0464","article-title":"TPCA-1 is a direct dual inhibitor of STAT3 and NF-kappaB and regresses mutant EGFR-associated human non-small cell lung cancers","volume":"13","author":"Nan","year":"2014","journal-title":"Mol. Cancer. Ther."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1124\/mol.107.041251","article-title":"Benzoxathiole derivative blocks lipopolysaccharide-induced nuclear factor-kappaB activation and nuclear factor-kappaB-regulated gene transcription through inactivating inhibitory kappaB kinase beta","volume":"73","author":"Kim","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1074\/jbc.M209677200","article-title":"BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice","volume":"278","author":"Burke","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1182\/blood-2004-08-3247","article-title":"A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors","volume":"105","author":"Tanaka","year":"2005","journal-title":"Blood"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"416036","DOI":"10.1155\/2012\/416036","article-title":"BAY 11-7082 is a broad-spectrum inhibitor with anti-inflammatory activity against multiple targets","volume":"2012","author":"Lee","year":"2012","journal-title":"Mediat. Inflamm."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1165\/rcmb.2006-0323OC","article-title":"Parthenolide inhibits IkappaB kinase, NF-kappaB activation, and inflammatory response in cystic fibrosis cells and mice","volume":"36","author":"Saadane","year":"2007","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1124\/mol.65.2.342","article-title":"Proteasome inhibitors induce inhibitory kappa B (I kappa B) kinase activation, I kappa B alpha degradation, and nuclear factor kappa B activation in HT-29 cells","volume":"65","author":"Nemeth","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1172\/JCI9826","article-title":"Inhibition of ubiquitin-proteasome pathway-mediated I kappa B alpha degradation by a naturally occurring antibacterial peptide","volume":"106","author":"Gao","year":"2000","journal-title":"J. Clin. Investig."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1074-5521(01)00056-4","article-title":"Proteasome inhibitors: From research tools to drug candidates","volume":"8","author":"Kisselev","year":"2001","journal-title":"Chem. Biol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.3892\/mmr.2014.2901","article-title":"GYY4137, a hydrogen sulfidereleasing molecule, inhibits the inflammatory response by suppressing the activation of nuclear factorkappa B and mitogenactivated protein kinases in Coxsackie virus B3infected rat cardiomyocytes","volume":"11","author":"Wu","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"10475","DOI":"10.1158\/0008-5472.CAN-07-2510","article-title":"Inhibition of nuclear factor-kappaB DNA binding by organoselenocyanates through covalent modification of the p50 subunit","volume":"67","author":"Chen","year":"2007","journal-title":"Cancer Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.bcp.2009.12.021","article-title":"Identification of known drugs that act as inhibitors of NF-\u03baB signaling and their mechanism of action","volume":"79","author":"Miller","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1203\/01.pdr.0000219120.92049.b3","article-title":"Dexamethasone suppresses expression of Nuclear Factor-kappaB in the cells of tracheobronchial lavage fluid in premature neonates with respiratory distress","volume":"59","author":"Aghai","year":"2006","journal-title":"Pediatric Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00011-010-0256-7","article-title":"Evidence that \u03b1-lipoic acid inhibits NF-\u03baB activation independent of its antioxidant function","volume":"60","author":"Ying","year":"2011","journal-title":"Inflamm. Res."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1074\/jbc.M115.679704","article-title":"Dimethyl fumarate inhibits the nuclear factor \u03baB pathway in breast cancer cells by covalent modification of p65 protein","volume":"291","author":"Kastrati","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2174\/1573408016999200708160300","article-title":"The Role of STAT3 Signaling in Different Types of Cancers: A Comprehensive Review","volume":"16","author":"Lakshmanan","year":"2020","journal-title":"Curr. Enzym. Inhib."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.3389\/fimmu.2018.01135","article-title":"A positive feedback amplifier circuit that regulates interferon (IFN)-stimulated gene expression and controls type I and type II IFN responses","volume":"9","author":"Michalska","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e25790","DOI":"10.4161\/jkst.25790","article-title":"STAT2 phosphorylation and signaling","volume":"2","author":"Steen","year":"2013","journal-title":"Jak-Stat."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Lee, C., and Cheung, S.T. (2019). STAT3: An emerging therapeutic target for hepatocellular carcinoma. Cancers, 11.","DOI":"10.3390\/cancers11111646"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"e999503","DOI":"10.1080\/21623996.2014.999503","article-title":"Role of STAT3 in lung cancer","volume":"3","author":"Dutta","year":"2014","journal-title":"Jak-Stat."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3389\/fonc.2019.00072","article-title":"Comparative STAT3-regulated gene expression profile in renal cell carcinoma subtypes","volume":"9","author":"Robinson","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"837","DOI":"10.7150\/jca.35011","article-title":"STAT3 signaling in ovarian cancer: A potential therapeutic target","volume":"11","author":"Liang","year":"2020","journal-title":"J. Cancer"},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Seffens, A., Herrera, A., Tegla, C., Buus, T.B., Hymes, K.B., \u00d8dum, N., Geskin, L.J., and Koralov, S.B. (2019). STAT3 dysregulation in mature T and NK cell lymphomas. Cancers, 11.","DOI":"10.3390\/cancers11111711"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12964-020-0527-z","article-title":"Role of STAT3 signaling pathway in breast cancer","volume":"18","author":"Ma","year":"2020","journal-title":"Cell Commun. Signal."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.7150\/ijbs.41852","article-title":"STAT4: An immunoregulator contributing to diverse human diseases","volume":"16","author":"Yang","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.mce.2017.04.025","article-title":"Crosstalk between STAT5 activation and PI3K\/AKT functions in normal and transformed mammary epithelial cells","volume":"451","author":"Wehde","year":"2017","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"e23060","DOI":"10.4161\/jkst.23060","article-title":"STAT heterodimers in immunity: A mixed message or a unique signal?","volume":"2","author":"Delgoffe","year":"2013","journal-title":"Jak-Stat"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0002-9440(10)64867-5","article-title":"Stat6-deficient mice develop airway hyperresponsiveness and peribronchial fibrosis during chronic fungal asthma","volume":"160","author":"Blease","year":"2002","journal-title":"Am. J. Pathol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.4049\/jimmunol.1600007","article-title":"STAT6 regulates the development of eosinophilic versus neutrophilic asthma in response to Alternaria alternata","volume":"197","author":"Valladao","year":"2016","journal-title":"J. Immunol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"e25301","DOI":"10.4161\/jkst.25301","article-title":"STAT6 and lung inflammation","volume":"2","author":"Walford","year":"2013","journal-title":"Jak-stat"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1034\/j.1600-065X.2001.790105.x","article-title":"The role of STAT6 in mast cell IL-4 production","volume":"179","author":"Sherman","year":"2001","journal-title":"Immunol. Rev."},{"key":"ref_164","first-page":"1146","article-title":"Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer\/T-cell lymphoma","volume":"132","author":"Song","year":"2018","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1242\/jcs.057109","article-title":"Stat3 promotes directional cell migration by regulating Rac1 activity via its activator \u03b2PIX","volume":"122","author":"Teng","year":"2009","journal-title":"J. Cell Sci."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/med.20101","article-title":"STAT3: A critical transcription activator in angiogenesis","volume":"28","author":"Chen","year":"2008","journal-title":"Med. Res. Rev."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1080\/1061186X.2018.1452244","article-title":"Bt354 as a new STAT3 signaling pathway inhibitor against triple negative breast cancer","volume":"26","author":"Chen","year":"2018","journal-title":"J. Drug Target."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-018-0992-z","article-title":"Osthole inhibits triple negative breast cancer cells by suppressing STAT3","volume":"37","author":"Dai","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-018-1139-z","article-title":"A new synthetic derivative of cryptotanshinone KYZ3 as STAT3 inhibitor for triple-negative breast cancer therapy","volume":"9","author":"Zhang","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-13-66","article-title":"Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo","volume":"13","author":"Sethi","year":"2014","journal-title":"Mol. Cancer"},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Lim, E.J., Hong, D.Y., Park, J.H., Joung, Y.H., Darvin, P., Kim, S.Y., Na, Y.M., Hwang, T.S., Ye, S.-K., and Moon, E.-S. (2012). Methylsulfonylmethane suppresses breast cancer growth by down-regulating STAT3 and STAT5b pathways. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0033361"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1158\/1535-7163.1533.3.12","article-title":"Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity","volume":"3","author":"Turkson","year":"2004","journal-title":"Mol. Cancer Ther."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/onc.2015.215","article-title":"Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo","volume":"35","author":"Huang","year":"2016","journal-title":"Oncogene"},{"key":"ref_174","first-page":"877","article-title":"Salidroside inhibits migration, invasion and angiogenesis of MDA-MB 231 TNBC cells by regulating EGFR\/Jak2\/STAT3 signaling via MMP2","volume":"53","author":"Kang","year":"2018","journal-title":"Int. J. Oncol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.4155\/fmc-2021-0088","article-title":"Discovery of novel STAT3 DNA binding domain inhibitors","volume":"13","author":"Wu","year":"2021","journal-title":"Future Med. Chem."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00281-012-0342-8","article-title":"Multifaceted roles of PGE2 in inflammation and cancer","volume":"35","author":"Nakanishi","year":"2013","journal-title":"Semin. Immunopathol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1126\/science.1068711","article-title":"Role of prostacyclin in the cardiovascular response to thromboxane A2","volume":"296","author":"Cheng","year":"2002","journal-title":"Science"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"926968","DOI":"10.1155\/2012\/926968","article-title":"PGI2 as a regulator of inflammatory diseases","volume":"2012","author":"Dorris","year":"2012","journal-title":"Mediat. Inflamm."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2217\/clp.10.11","article-title":"Thromboxane and the thromboxane receptor in cardiovascular disease","volume":"5","author":"Smyth","year":"2010","journal-title":"Clin. Lipidol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/eurheartj\/11.suppl_B.27","article-title":"Thromboxane A2 and platelets as mediators of coronary arterial vasoconstriction in myocardial ischaemia","volume":"11","year":"1990","journal-title":"Eur. Heart J."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1253\/jcj.51.495","article-title":"Thromboxane A2 as an enhancing factor of coronary vasospasticity in variant angina","volume":"51","author":"Ohmori","year":"1987","journal-title":"Jpn. Circ. J."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10555-011-9297-9","article-title":"The thromboxane synthase and receptor signaling pathway in cancer: An emerging paradigm in cancer progression and metastasis","volume":"30","author":"Ekambaram","year":"2011","journal-title":"Cancer Metastasis Rev."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"e2154","DOI":"10.1038\/cddis.2016.61","article-title":"GW627368X inhibits proliferation and induces apoptosis in cervical cancer by interfering with EP4\/EGFR interactive signaling","volume":"7","author":"Parida","year":"2016","journal-title":"Cell Death Dis."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1124\/jpet.107.122010","article-title":"CJ-023,423, a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties","volume":"322","author":"Nakao","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1161\/01.CIR.72.6.1208","article-title":"AH23848: A thromboxane receptor-blocking drug that can clarify the pathophysiologic role of thromboxane A2","volume":"72","author":"Brittain","year":"1985","journal-title":"Circulation"},{"key":"ref_186","first-page":"3","article-title":"Role of cyclooxygenase isoforms in gastric mucosal defence","volume":"95","author":"Peskar","year":"2001","journal-title":"J. Physiol."},{"key":"ref_187","first-page":"906","article-title":"Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer","volume":"63","author":"Gupta","year":"2003","journal-title":"Cancer Res."},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Haakensen, V.D., Bj\u00f8ro, T., L\u00fcders, T., Riis, M., Bukholm, I.K., Kristensen, V.N., Troester, M.A., Homen, M.M., Ursin, G., and B\u00f8rresen-Dale, A.-L. (2011). Serum estradiol levels associated with specific gene expression patterns in normal breast tissue and in breast carcinomas. BMC Cancer, 11.","DOI":"10.1186\/1471-2407-11-332"},{"key":"ref_189","first-page":"424","article-title":"Cyclooxygenase-1 is up-regulated in cervical carcinomas: Autocrine\/paracrine regulation of cyclooxygenase-2, prostaglandin e receptors, and angiogenic factors by cyclooxygenase-1","volume":"62","author":"Sales","year":"2002","journal-title":"Cancer Res."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"677","DOI":"10.5306\/wjco.v5.i4.677","article-title":"Cyclooxygenase-2 and the inflammogenesis of breast cancer","volume":"5","author":"Harris","year":"2014","journal-title":"World J. Clin. Oncol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0090-4295(01)01255-9","article-title":"The role of cyclooxygenase-2 in prostate cancer","volume":"58","author":"Kirschenbaum","year":"2001","journal-title":"Urology"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1038\/onc.2017.73","article-title":"Hepatic cyclooxygenase-2 overexpression induced spontaneous hepatocellular carcinoma formation in mice","volume":"36","author":"Chen","year":"2017","journal-title":"Oncogene"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12935-015-0260-7","article-title":"Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity","volume":"15","author":"Liu","year":"2015","journal-title":"Cancer Cell Int."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/j.seminoncol.2004.03.040","article-title":"Multiple roles of COX-2 in tumor angiogenesis: A target for antiangiogenic therapy","volume":"31","author":"Gately","year":"2004","journal-title":"Semin. Oncol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"e1806","DOI":"10.1097\/MD.0000000000001806","article-title":"COX-2 promotes migration and invasion by the side population of cancer stem cell-like hepatocellular carcinoma cells","volume":"94","author":"Guo","year":"2015","journal-title":"Medicine"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1039\/C8NJ04385J","article-title":"A novel class of tyrosine derivatives as dual 5-LOX and COX-2\/mPGES1 inhibitors with PGE 2 mediated anticancer properties","volume":"43","author":"Puratchikody","year":"2019","journal-title":"New J. Chem."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"684","DOI":"10.7326\/0003-4819-121-9-199411010-00010","article-title":"The role of leukotrienes in inflammation","volume":"121","author":"Henderson","year":"1994","journal-title":"Ann. Intern. Med."},{"key":"ref_198","first-page":"273","article-title":"Mediation of leukocyte components of inflammatory reactions by lipoxygenase products of arachidonic acid","volume":"9","author":"Goetzl","year":"1982","journal-title":"Adv. Prostaglandin Thromboxane Leukot. Res."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.3390\/cancers6031500","article-title":"Inflammation, cancer and oxidative lipoxygenase activity are intimately linked","volume":"6","author":"Wisastra","year":"2014","journal-title":"Cancers"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00384-010-0980-z","article-title":"Overexpression of 5-lipoxygenase in sporadic colonic adenomas and a possible new aspect of colon carcinogenesis","volume":"25","author":"Wasilewicz","year":"2010","journal-title":"Int. J. Colorectal Dis."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0090-4295(99)80198-8","article-title":"Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer","volume":"46","author":"Gao","year":"1995","journal-title":"Urology"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.canlet.2005.03.025","article-title":"Elevated 12-and 20-hydroxyeicosatetraenoic acid in urine of patients with prostatic diseases","volume":"233","author":"Nithipatikom","year":"2006","journal-title":"Cancer Lett."},{"key":"ref_203","first-page":"RCT3784","article-title":"Late Breaking Abstract-Effect of timapiprant, a DP2 antagonist, on airway inflammation in severe eosinophilic asthma","volume":"54","author":"Shrimanker","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1164\/rccm.200710-1519OC","article-title":"Role of the prostanoid EP4 receptor in iloprost-mediated vasodilatation in pulmonary hypertension","volume":"178","author":"Lai","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1700670","DOI":"10.1183\/13993003.00670-2017","article-title":"Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids","volume":"50","author":"Bateman","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_206","first-page":"1251","article-title":"Efficacy and safety of bimatoprost in glaucoma and ocular hypertension in non-responder patients","volume":"10","author":"Brennan","year":"2017","journal-title":"Int. J. Ophthalmol."},{"key":"ref_207","unstructured":"Ghlichloo, I., and Gerriets, V. (2021). Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), StatPearls."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/0091-6749(87)90240-5","article-title":"The effect of sodium meclofenamate in premenstrual asthma: A controlled clinical trial","volume":"79","author":"Eliasson","year":"1987","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1164\/ajrccm.157.4.9707089","article-title":"Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics","volume":"157","author":"Dahlen","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1021\/acs.jnatprod.9b00403","article-title":"Myxochelin-and Pseudochelin-Derived Lipoxygenase Inhibitors from a Genetically Engineered Myxococcus xanthus Strain","volume":"82","author":"Sester","year":"2019","journal-title":"J. Nat. Prod."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"a026831","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC inhibitors in cancer development and therapy","volume":"6","author":"Li","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canlet.2008.08.016","article-title":"HDAC family: What are the cancer relevant targets?","volume":"277","author":"Witt","year":"2009","journal-title":"Cancer Lett."},{"key":"ref_213","doi-asserted-by":"crossref","unstructured":"Liu, N., He, S., Ma, L., Ponnusamy, M., Tang, J., Tolbert, E., Bayliss, G., Zhao, T.C., Yan, H., and Zhuang, S. (2013). Blocking the class I histone deacetylase ameliorates renal fibrosis and inhibits renal fibroblast activation via modulating TGF-beta and EGFR signaling. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0054001"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"9429","DOI":"10.1074\/jbc.M109.071274","article-title":"Histone deacetylase-3 activation promotes tumor necrosis factor-\u03b1 (TNF-\u03b1) expression in cardiomyocytes during lipopolysaccharide stimulation","volume":"285","author":"Zhu","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/nar\/gks916","article-title":"The coactivator role of histone deacetylase 3 in IL-1-signaling involves deacetylation of p65 NF-\u03baB","volume":"41","author":"Ziesche","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"ref_216","doi-asserted-by":"crossref","unstructured":"Durham, B.S., Grigg, R., and Wood, I.C. (2017). Inhibition of histone deacetylase 1 or 2 reduces microglia activation through a gene expression independent mechanism. bioRxiv, 107649.","DOI":"10.1101\/107649"},{"key":"ref_217","doi-asserted-by":"crossref","unstructured":"Yoon, S., Kang, G., and Eom, G.H. (2019). HDAC inhibitors: Therapeutic potential in fibrosis-associated human diseases. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061329"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.matbio.2010.05.002","article-title":"HDAC-mediated control of ERK-and PI3K-dependent TGF-\u03b2-induced extracellular matrix-regulating genes","volume":"29","author":"Barter","year":"2010","journal-title":"Matrix Biol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1365-2222.2004.02006.x","article-title":"Trichostatin A attenuates airway inflammation in mouse asthma model","volume":"35","author":"Choi","year":"2005","journal-title":"Clin. Exp. Allergy"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"105973","DOI":"10.1016\/j.intimp.2019.105973","article-title":"Trichostatin A modulates the macrophage phenotype by enhancing autophagy to reduce inflammation during polymicrobial sepsis","volume":"77","author":"Cui","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/j.cellsig.2013.05.007","article-title":"Regulation of STAT signaling by acetylation","volume":"25","author":"Zhuang","year":"2013","journal-title":"Cell. Signal."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1038\/oncsis.2012.23","article-title":"Evaluation of epigenetic modulation of cyclooxygenase-2 as a prognostic marker for hepatocellular carcinoma","volume":"1","author":"Mayoral","year":"2012","journal-title":"Oncogenesis"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4155\/fmc.12.3","article-title":"Targeted cancer therapy: Giving histone deacetylase inhibitors all they need to succeed","volume":"4","author":"Gryder","year":"2012","journal-title":"Future Med. Chem."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.0022-202X.2005.23925.x","article-title":"Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: Relevance to mechanism of therapeutic action","volume":"125","author":"Zhang","year":"2005","journal-title":"J. Investig. Dermatol."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.2217\/fon.15.62","article-title":"Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma","volume":"11","author":"Rashidi","year":"2015","journal-title":"Future Oncol."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2147\/OTT.S93528","article-title":"Chidamide in the treatment of peripheral T-cell lymphoma","volume":"10","author":"Chan","year":"2017","journal-title":"OncoTargets Ther."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1586\/era.10.88","article-title":"Romidepsin: A new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors","volume":"10","author":"Grant","year":"2010","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_228","first-page":"84","article-title":"Farydak (Panobinostat): First HDAC inhibitor approved for patients with relapsed multiple myeloma","volume":"9","author":"Raedler","year":"2016","journal-title":"Am. Health Drug Benefits"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1080\/14756366.2017.1417274","article-title":"Zinc binding groups for histone deacetylase inhibitors","volume":"33","author":"Zhang","year":"2018","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1021\/ml400158k","article-title":"Tropolones as lead-like natural products: The development of potent and selective histone deacetylase inhibitors","volume":"4","author":"Ononye","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"1600744","DOI":"10.1002\/mnfr.201600744","article-title":"Targeting the epigenome: Screening bioactive compounds that regulate histone deacetylase activity","volume":"61","author":"Godoy","year":"2017","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1021\/jm301769u","article-title":"3-Hydroxypyridin-2-thione as novel zinc binding group for selective histone deacetylase inhibition","volume":"56","author":"Patil","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"9969","DOI":"10.1021\/jm401225q","article-title":"Synthesis and structure\u2013activity relationship of 3-hydroxypyridine-2-thione-based histone deacetylase inhibitors","volume":"56","author":"Sodji","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.bmcl.2007.12.031","article-title":"Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1\/HDAC2 inhibitors (SHI-1: 2)","volume":"18","author":"Methot","year":"2008","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2174\/1568026619666190122144949","article-title":"Zinc-dependent deacetylase (HDAC) inhibitors with different zinc binding groups","volume":"19","author":"Li","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"126926","DOI":"10.1016\/j.bmcl.2019.126926","article-title":"Potent non-hydroxamate inhibitors of histone deacetylase-8: Role and scope of an isoindolin-2-yl linker with an \u03b1-amino amide as the zinc-binding unit","volume":"30","author":"Greenwood","year":"2020","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"505101","DOI":"10.1088\/0957-4484\/23\/50\/505101","article-title":"Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice","volume":"23","author":"Trivedi","year":"2012","journal-title":"Nanotechnology"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41413-017-0005-4","article-title":"Transforming growth factor-\u03b2 in stem cells and tissue homeostasis","volume":"6","author":"Xu","year":"2018","journal-title":"Bone Res."},{"key":"ref_239","doi-asserted-by":"crossref","unstructured":"Takai, E., Tsukimoto, M., and Kojima, S. (2013). TGF-\u03b21 downregulates COX-2 expression leading to decrease of PGE2 production in human lung cancer A549 cells, which is involved in fibrotic response to TGF-\u03b21. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0076346"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1177\/0192623311416259","article-title":"Induction of heart valve lesions by small-molecule ALK5 inhibitors","volume":"39","author":"Anderton","year":"2011","journal-title":"Toxicol. Pathol."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3389\/fcell.2020.00605","article-title":"On-Target Anti-TGF-\u03b2 Therapies Are Not Succeeding in Clinical Cancer Treatments: What Are Remaining Challenges?","volume":"8","author":"Teixeira","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_242","first-page":"S17","article-title":"Predicting life expectancy for pirfenidone in idiopathic pulmonary fibrosis","volume":"23","author":"Fisher","year":"2017","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_243","doi-asserted-by":"crossref","unstructured":"Jiang, J.-H., and Deng, P. (2019). Discovery of new inhibitors of transforming growth factor-beta type 1 receptor by utilizing docking and structure-activity relationship analysis. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20174090"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1124\/mol.62.1.65","article-title":"SB-431542 is a potent and specific inhibitor of transforming growth factor-\u03b2 superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7","volume":"62","author":"Inman","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1158\/1535-7163.MCT-07-0337","article-title":"LY2109761, a novel transforming growth factor \u03b2 receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis","volume":"7","author":"Melisi","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_246","first-page":"4479","article-title":"Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway","volume":"9","author":"Herbertz","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_247","unstructured":"Tauriello, D.B., Daniel, M.M., Joan, A., Batlle, G., and Riera Escal\u00e9, E.A. (2020). TGF\u03b2 Inhibitor and Prodrugs. (International Patent Application No. PCT\/EP2019\/082215; WO\/2020\/104648)."},{"key":"ref_248","unstructured":"Wu, B. (2021). Discovery of Novel Drugs with Tissue and Cell-Type Selectivity for Cancer and Inflammation. [Ph.D. Thesis, Georgia Institute of Technology]."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1158\/1078-0432.CCR-15-1374","article-title":"Molecular pathways: The balance between cancer and the immune system challenges the therapeutic specificity of targeting nuclear factor-\u03baB signaling for cancer treatment","volume":"22","author":"Zeligs","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s10637-010-9474-7","article-title":"A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma","volume":"29","author":"Shah","year":"2011","journal-title":"Investig. New Drugs"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1158\/0008-5472.CAN-09-3912","article-title":"Activation of NF-\u03baB signaling by inhibitor of NF-\u03baB kinase \u03b2 increases aggressiveness of ovarian cancer","volume":"70","author":"Hernandez","year":"2010","journal-title":"Cancer Res."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1042\/BST20150014","article-title":"Dissecting molecular cross-talk between Nrf2 and NF-\u03baB response pathways","volume":"43","author":"Wardyn","year":"2015","journal-title":"Biochem. Soc. Trans."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/brain\/awq386","article-title":"Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway","volume":"134","author":"Linker","year":"2011","journal-title":"Brain"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1128\/MCB.26.1.221-229.2006","article-title":"Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1","volume":"26","author":"Kobayashi","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/med.21567","article-title":"Dimethyl fumarate, a two-edged drug: Current status and future directions","volume":"39","author":"Saidu","year":"2019","journal-title":"Med. Res. Rev."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jnutbio.2006.11.012","article-title":"Piperine protects cisplatin-induced apoptosis via heme oxygenase-1 induction in auditory cells","volume":"18","author":"Choi","year":"2007","journal-title":"J. Nutr. Biochem."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11910-013-0394-8","article-title":"Dimethyl fumarate for treatment of multiple sclerosis: Mechanism of action, effectiveness, and side effects","volume":"13","author":"Linker","year":"2013","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"E6199","DOI":"10.1073\/pnas.1608245113","article-title":"Suppression of NF-\u03baB activity via nanoparticle-based siRNA delivery alters early cartilage responses to injury","volume":"113","author":"Yan","year":"2016","journal-title":"Procl. Natl. Acad. Sci. USA"},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1039\/c3nr30071d","article-title":"Gold nanoparticles induce transcriptional activity of NF-\u03baB in a B-lymphocyte cell line","volume":"5","author":"Sharma","year":"2013","journal-title":"Nanoscale"},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1080\/21691401.2018.1446968","article-title":"Nano-gold displayed anti-inflammatory property via NF-kB pathways by suppressing COX-2 activity","volume":"46","author":"Khan","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"119997","DOI":"10.1016\/j.biomaterials.2020.119997","article-title":"Catcher in the rel: Nanoparticles-antibody conjugate as NF-\u03baB nuclear translocation blocker","volume":"246","author":"Chen","year":"2020","journal-title":"Biomaterials"},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-017-0612-3","article-title":"YAP transcriptionally regulates COX-2 expression and GCCSysm-4 (G-4), a dual YAP\/COX-2 inhibitor, overcomes drug resistance in colorectal cancer","volume":"36","author":"Li","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1093\/carcin\/bgs367","article-title":"Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling","volume":"34","author":"Wang","year":"2013","journal-title":"Carcinogenesis"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-03-0463","article-title":"Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments","volume":"10","author":"Dang","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa050405","article-title":"Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention","volume":"352","author":"Solomon","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/014107680609900315","article-title":"Risk of cardiovascular events and celecoxib: A systematic review and meta-analysis","volume":"99","author":"Caldwell","year":"2006","journal-title":"J. R. Soc. Med."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0149-2918(03)80110-8","article-title":"Valdecoxib: A review","volume":"25","author":"Chavez","year":"2003","journal-title":"Clin. Ther."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.2174\/092986710793205408","article-title":"Selective COX-1 inhibition: A therapeutic target to be reconsidered","volume":"17","author":"Perrone","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"i16","DOI":"10.1093\/rheumatology\/keh104","article-title":"Safety of anti-inflammatory treatment\u2014New ways of thinking","volume":"43","author":"Brune","year":"2004","journal-title":"Rheumatology"},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3390\/cancers6020926","article-title":"Transcription factor STAT3 as a novel molecular target for cancer prevention","volume":"6","author":"Xiong","year":"2014","journal-title":"Cancers"},{"key":"ref_271","doi-asserted-by":"crossref","unstructured":"Huang, Y.-H., Vakili, M.R., Molavi, O., Morrissey, Y., Wu, C., Paiva, I., Soleimani, A.H., Sanaee, F., Lavasanifar, A., and Lai, R. (2019). Decoration of anti-CD38 on nanoparticles carrying a STAT3 inhibitor can improve the therapeutic efficacy against myeloma. Cancers, 11.","DOI":"10.20944\/preprints201901.0114.v1"},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1038\/s41388-020-01454-1","article-title":"Combined inhibition of JAK2-STAT3 and SMO-GLI1\/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis","volume":"39","author":"Doheny","year":"2020","journal-title":"Oncogene"},{"key":"ref_273","doi-asserted-by":"crossref","unstructured":"Zerdes, I., Wallerius, M., Sifakis, E.G., Wallmann, T., Betts, S., Bartish, M., Tsesmetzis, N., Tobin, N.P., Coucoravas, C., and Bergh, J. (2019). STAT3 activity promotes programmed-death ligand 1 expression and suppresses immune responses in breast cancer. Cancers, 11.","DOI":"10.3390\/cancers11101479"},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.imlet.2019.10.003","article-title":"Impact of combination therapy with anti-PD-1 blockade and a STAT3 inhibitor on the tumor-infiltrating lymphocyte status","volume":"216","author":"Ashizawa","year":"2019","journal-title":"Immunol. Lett."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"ref_276","doi-asserted-by":"crossref","unstructured":"Nezamololama, N., Fieldhouse, K., Metzger, K., and Gooderham, M. (2020). Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: A review of abrocitinib, baricitinib, and upadacitinib. Drugs Context, 9.","DOI":"10.7573\/dic.2020-8-5"},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/nrurol.2010.185","article-title":"The epigenome as a therapeutic target in prostate cancer","volume":"7","author":"Perry","year":"2010","journal-title":"Nat. Rev. Urol."},{"key":"ref_278","doi-asserted-by":"crossref","unstructured":"Freese, K., Seitz, T., Dietrich, P., Lee, S.M., Thasler, W.E., Bosserhoff, A., and Hellerbrand, C. (2019). Histone deacetylase expressions in hepatocellular carcinoma and functional effects of histone deacetylase inhibitors on liver cancer cells in vitro. Cancers, 11.","DOI":"10.3390\/cancers11101587"},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"4822","DOI":"10.1158\/1078-0432.CCR-04-0349","article-title":"Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But","volume":"10","author":"Coradini","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_280","first-page":"579","article-title":"Apoptosis and tumor remission in liver tumor xenografts by 4-phenylbutyrate","volume":"22","author":"Svechnikova","year":"2003","journal-title":"Int. J. Oncol."},{"key":"ref_281","doi-asserted-by":"crossref","unstructured":"Tapadar, S., Fathi, S., Wu, B., Sun, C.Q., Raji, I., Moore, S.G., Arnold, R.S., Gaul, D.A., Petros, J.A., and Oyelere, A.K. (2020). Liver-targeting class I selective histone deacetylase inhibitors potently suppress hepatocellular tumor growth as standalone agents. Cancers, 12.","DOI":"10.3390\/cancers12113095"},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fonc.2018.00092","article-title":"Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: Achieving the full therapeutic potential of HDACi","volume":"8","author":"Suraweera","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.biocel.2018.03.004","article-title":"HDAC inhibitors as epigenetic regulators for cancer immunotherapy","volume":"98","author":"Conte","year":"2018","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.18632\/oncotarget.2289","article-title":"HDAC inhibitors and immunotherapy; a double edged sword?","volume":"5","author":"Kroesen","year":"2014","journal-title":"Oncotarget"},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/s41375-018-0062-8","article-title":"Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors","volume":"32","author":"Bae","year":"2018","journal-title":"Leukemia"},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00262-017-2091-y","article-title":"The class I\/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy","volume":"67","author":"Briere","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1158\/2326-6066.CIR-15-0077-T","article-title":"HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade","volume":"3","author":"Woods","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1525-0016(03)00235-1","article-title":"A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis","volume":"8","author":"Chung","year":"2003","journal-title":"Mol. Ther."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"2040622319862697","DOI":"10.1177\/2040622319862697","article-title":"HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis","volume":"10","author":"Lyu","year":"2019","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/sj.bjp.0707166","article-title":"HDAC inhibitors as anti-inflammatory agents","volume":"150","author":"Adcock","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0008-8749(02)00523-3","article-title":"Trichostatin A, a histone deacetylase inhibitor, down-regulates interleukin-12 transcription in SV-40-transformed lung epithelial cells","volume":"218","author":"Iwata","year":"2002","journal-title":"Cell. Immunol."},{"key":"ref_292","doi-asserted-by":"crossref","unstructured":"Weiss, U., M\u00f6ller, M., Husseini, S.A., Manderscheid, C., H\u00e4usler, J., Geisslinger, G., and Niederberger, E. (2020). Inhibition of HDAC Enzymes Contributes to Differential Expression of Pro-Inflammatory Proteins in the TLR-4 Signaling Cascade. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21238943"},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1210\/en.2009-1318","article-title":"Gonadotropins induce tumor cell migration and invasion by increasing cyclooxygenases expression and prostaglandin E2 production in human ovarian cancer cells","volume":"151","author":"Lau","year":"2010","journal-title":"Endocrinology"},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejmech.2019.06.039","article-title":"Targeting COX-1 by mofezolac-based fluorescent probes for ovarian cancer detection","volume":"179","author":"Scilimati","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"e23353","DOI":"10.4161\/jkst.23353","article-title":"The tumor suppressor function of STAT1 in breast cancer","volume":"2","author":"Koromilas","year":"2013","journal-title":"Jak-Stat."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"6037","DOI":"10.2147\/OTT.S256708","article-title":"Targeting IFN\/STAT1 Pathway as a Promising Strategy to Overcome Radioresistance","volume":"13","author":"Liu","year":"2020","journal-title":"OncoTargets Ther."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1111\/jcmm.13882","article-title":"STAT 1 facilitates oestrogen receptor \u03b1 transcription and stimulates breast cancer cell proliferation","volume":"22","author":"Hou","year":"2018","journal-title":"J. Cell. Mol. Med."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-018-0773-8","article-title":"Physical interaction of STAT1 isoforms with TGF-\u03b2 receptors leads to functional crosstalk between two signaling pathways in epithelial ovarian cancer","volume":"37","author":"Tian","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat. Methods"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/3\/552\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:05:49Z","timestamp":1760133949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/3\/552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,22]]},"references-count":299,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["cancers14030552"],"URL":"https:\/\/doi.org\/10.3390\/cancers14030552","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,22]]}}}